Skip to main content
. 2012 Mar;1(1):72–77. doi: 10.3978/j.issn.2218-6751.2011.12.04

Table 3. Outcome of multi-targeted vs. mono-targeted TKIs in NSCLC.

Study Drug n Median PFS (week) Median OS (week) ORR (%) DCR (%)
Socinski Sunitinib 63 11.3 24 9.5 52
Blumenschein Sorafenib 52 11.9 29 0 59
Ronald B Vandetanib 83 11 24 8 45
BR21 Erlotinib 488 9.4 28.7 6.9 43.0
Interest Gefitinib 659 9.4 32.6 9.7 45.8

DCR: disease control rate.